A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

Investigative Site DE005, Berlin

Investigative Site ES002, Córdoba

Investigative Site ES006, Granada

Investigative Site DE001, Hamburg

Investigative Site US003, Baltimore

Investigative Site ES008, Madrid

Investigative Site ES003, Madrid

Investigative Site 1071320, Newnan

Investigative Site US013, Miramar

Investigative Site US016, Miami

Investigative Site US019, Fort Lauderdale

Investigative Site US022, Murfreesboro

Investigative Site US002, Dublin

Investigative Site US012, Gahanna

Investigative Site US023, Athens

Investigative Site ES005, Valencia

Investigative Site US008, Plainfield

Investigative Site US011, South Bend

Investigative Site US017, Troy

Investigative Site DE002, Münster

Investigative Site DE007, Bad Bentheim

Investigative Site DE004, Bonn

Investigative Site DE003, Frankfurt am Main

Investigative Site US006, Saint Joseph

Investigative Site DE008, Tübingen

Investigative Site US018, Dallas

Investigative Site US021, Arlington

Investigative Site US007, Houston

Investigative Site US005, Austin

Investigative Site US010, Phoenix

Investigative Site US024, Phoenix

Investigative Site PL004, Torun

Investigative Site US001, Fountain Valley

Investigative Site US014, Sacramento

Investigative Site PL005, Kielce

Investigative Site US009, Tampa

Investigative Site US004, Portsmouth

Investigative Site CA002, Edmonton

Investigative Site CA001, Surrey

Investigative Site CA004, London

Investigative Site CA003, Québec

Investigative Site PL003, Osielsko

Investigative Site PL001, Rzeszów

Investigative Site PL002, Wroclaw

Investigative Site PR002, Caguas

Investigative Site PR001, San Juan

Investigative Site ES004, Alicante

Investigative Site ES007, Badalona

Investigative Site ES001, Barcelona